Half of new MS patients may soon get Biogen’s Tecfidera Boston-based financial services group Cowen Group Inc. said Friday morning that based on patient data, Biogen Idec Inc.’s new drug, Tecfidera, may soon be getting more than half of all new multiple sclerosis patients. The Weston, Mass. biotech launched Tecfidera in March and has managed to outdo already-high expectations ever since. During its first three months on the market, the drug accounted for more than 10 percent of the Weston, Mass.-based drug company’s second-quarter revenues of $1.7 billion, which was up 21 percent year-over-year.
Cannabis was extensively used as a medicine throughout the developed world in the nineteenth century but went into decline early in the twentieth century ahead of its emergence as the most widely used illicit recreational drug later that century. This paper will then go on to review clinical research exploring the potential of cannabinoid medicines in the following indications: symptomatic relief in multiple sclerosis, chronic neuropathic pain, intractable nausea and vomiting, loss of appetite and weight in the context of cancer or AIDS, psychosis, epilepsy, addiction, and metabolic disorders.
